22:19 , Jun 19, 2019 |  BC Extra  |  Company News

June 19 Company Quick Takes: Catalent takes over manufacturing site from BMS; plus Lynparza, Myriad, Amgen and more

Catalent buys Italian facility from BMS  Catalent Inc. (NYSE:CTLT) will buy an Italian manufacturing facility from Bristol-Myers Squibb Co. (NYSE:BMY) for an undisclosed amount. Catalent will manufacture oral solid, biologics and sterile products at the...
00:02 , Jun 19, 2019 |  BC Extra  |  Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

CTTQ, Akeso form JV to develop PD-1 mAb  The Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) subsidiary of Sino Biopharmaceutical Ltd. (HKEX:1177) formed a 50/50 joint venture with Akeso Biopharma Inc. (Zhongshan, China) to...
07:00 , May 23, 2016 |  BC Week In Review  |  Company News

Cell Therapy, Daiichi Sankyo deal

Cell Therapy granted Daiichi Sankyo exclusive rights to develop and commercialize Heartcel allogeneic immunomodulatory progenitor (iMP) cells in Japan. Cell Therapy received a L12.5 million ($17.9 million) upfront licensing fee and is eligible for additional...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

Allogeneic iMP cells: Phase II data

The Phase II HeartCel trial in advanced heart failure patients at high risk of incomplete revascularization with coronary artery bypass graft (CABG) surgery showed that allogeneic iMP cells injected intra-myocardially led to a 100% MACE-free...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

Tendoncel: Phase II data

A double-blind, placebo-controlled Phase II trial in 34 patients with chronic grade 3 lateral epicondylitis showed that once-daily topical Tendoncel for 21 days significantly improved DASH scores by 70% and PRTEE scores by 74%. Tendoncel...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Company News

Cell Therapy, Zhongyuan Union Stem Cell Bioengineering Corp. deal

The partners formed a JV to develop stem cell therapies to treat heart failure patients in China. The deal will establish the JV in multiple Chinese cities with large operational hubs near Shanghai and Beijing....